Get access to the most advanced embryo screening through Orchid’s CLIA/CAP-certified laboratoryget access
Tell your doctor you'd like to screen your embryos with Orchid
Receive advanced genetic reports for each embryo
Board-certified genetic counselors walk you through your results
Orchid reads >99% of an embryo’s DNA (most competitors read less than 1%), so we can screen for the genetic causes of thousands of conditions simultaneously.
Triploidy, Molar pregnancy
Traditional PGT-M without probes
Screen for hundreds of monogenic disorders simultaneously
PGT-M plus hundreds of monogenic disorders associated with severe disease
Genetic Risk Scores
High-quality results start with high-quality, comprehensive data. We sequence the full genome of each embryo to provide the most advanced genetic risk assessment available.
We focus on maximizing the chance for a healthy pregnancy and child by reducing the risk for severe genetic diseases. We also focus on measuring genetic susceptibility to chronic diseases that affect over 60% of the population.
We’ve partnered with top reproductive medicine doctors, statistical geneticists, and medical geneticists to help validate our technology. We’re trusted by leading fertility clinics.
Speak with your fertility doctor, who can order Orchid's embryo testing on your behalf.
Embryologists carefully prepare your samples and send them to our CAP/CLIA certified lab for analysis.
We sequence your samples, and return a comprehensive report for each embryo.
Receive a report for each embryo based on the screening test you selected to inform your transfer plan.
Board-certified genetic counselors are available to answer your questions.
Convenient online scheduling with evening and weekend availability.
We’ll show you an example embryo report so you know exactly what you’ll learn.Schedule demo
Only Orchid can offer one screen that combines PGT-A, PGT-M, screens for hundreds of genes linked to severe disease, and measures genetic predisposition to disease. These are all screened simultaneously from the same embryo biopsy used in traditional testing.Read more
Clinical Assistant Professor at the Stanford Medical Center
Professor of Obstetrics and Gynecology at the Stanford Medical Center
Reproductive Endocrinologist at RMA
Screening your embryos created through IVF allows you to quantify each embryo’s genetic risk for severe monogenic disease and genetic predispositions to: Alzheimer’s disease, atrial fibrillation, bipolar disorder, breast cancer, celiac disease, class III obesity, coronary artery disease, inflammatory bowel disease, prostate cancer, schizophrenia, type 1 diabetes, and type 2 diabetes. These results can help inform your transfer plan by prioritizing transferring embryos with the lowest genetic risk.
Orchid embryo test is the most advanced genetic risk assessment available.
Our embryo report measures genetic predisposition for severe monogenic conditions and common conditions not included in other embryo genetic testing. PGT-A is included in Orchid’s test and is applicable to any couple, PGT-M is also available on Orchid's PGT-WGS.
Currently, the different subtypes of preimplantation genetic testing (PGT) are referred to as:
PGT-A (for aneuploidy) - screens for the number of chromosomes present to increase the chance of a successful pregnancy. Orchid’s embryo test includes PGT-A.
PGT-M (for monogenic conditions) - used only for individuals or couples with a known risk of passing down a single gene disorder such as cystic fibrosis or Huntington’s disease. Orchid's PGT-WGS includes PGT-M if required.
PGT-SR (for structural rearrangements) - used only for individuals with a chromosome rearrangement like a translocation or inversion.
For the first time ever, couples can safely and naturally reduce their future children’s genetic risk for the top 12 most common diseases.
For each embryo, Orchid sequences over 3 billion data points across the genome from the three to five cells carefully sampled and sent to our lab. Since each embryo has different DNA, each embryo has different genetic risks for chronic, common diseases.
This is done by comparing the genetic makeup of hundreds of thousands of individuals diagnosed with the conditions we screen for (“cases”) with individuals without diseases (“controls”). Results from the embryo report can help inform your transfer plan to mitigate health risks for your future family.
Learn more with a deeper dive into our science.
Your privacy is our top priority. We handle sensitive, personal information, and biological samples and we don’t take that lightly.
We guarantee that:
We do not sell your data to any third party, ever.
You can ask us to delete your data at any time, but this will mean that you cannot access the Orchid service to view your reports anymore.